EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy

Cem Onal iD, Aysenur Elmali iD, Birhan Demirhan iD, Ertugrul Senturk, Petek Erpolat, Ozan Cem Guler iD

The Prostate · 2026-06 · 86 (8) · 961-969

DOI: 10.1002/pros.70167 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Prostate, online erschienen am 30.03.2026. Verfasst von Cem Onal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkiye. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Unfavorable intermediate‐risk prostate cancer (UIR‐PCa) represents a biologically heterogeneous subgroup with a higher risk of recurrence compared with favorable intermediate‐risk disease. Contemporary management frequently includes dose‐escalated radiotherapy (RT) combined with short‐term androgen deprivation therapy (ADT). Whether additional intraprostatic dose escalation using a simultaneous integrated boost (SIB) provides incremental oncologic benefit in this setting remains uncertain.

Methods

We retrospectively analyzed 194 patients with UIR‐PCa treated at three institutions between 2010 and 2023. All patients received image‐guided intensity‐modulated or volumetric modulated arc RT to 78 Gy with short‐term ADT. An MRI‐guided intraprostatic SIB (up to 86 Gy) was delivered in 77 patients (39.7%) at clinician discretion. Primary endpoints were biochemical recurrence‐free survival (bRFS), distant metastasis‐free survival (DMFS), and prostate cancer–specific mortality (PCSM). Multivariable Cox and competing‐risk regression models were used to assess predictors of outcome.

Results

After a median follow‐up of 105 months, 8‐year bRFS and DMFS rates for the entire cohort were 93.7% and 95.7%, respectively. Addition of SIB was not associated with improved bRFS (93.5% vs 93.6%, p = 0.36), DMFS (94.6% vs 96.7%, p = 0.15), or PCSM. Percent positive biopsy cores ≥ 50% was the only independent predictor of inferior bRFS on multivariable analysis. Treatment‐related toxicity was low in both groups, with no significant differences in late grade ≥ 2 gastrointestinal or genitourinary toxicity.

Conclusions

In patients with UIR‐PCa uniformly treated with dose‐escalated, image‐guided RT and short‐term ADT, long‐term oncologic outcomes were excellent. The addition of an intraprostatic SIB was safe but did not confer measurable improvement in biochemical or distant disease control. These findings support a selective rather than routine use of focal intraprostatic dose escalation in contemporary UIR‐PCa management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatic NeoplasmsRadiotherapy, Intensity-ModulatedAgedAged, 80 and overHumansMaleMiddle AgedRadiotherapy DosageRadiotherapy, Image-GuidedRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

androgen deprivation therapyintermediate riskprostate cancerradiotherapysimultaneous integrated boost

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkiye.
  • Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye.
  • Division of Radiation Oncology, Iskenderun Gelisim Hospital, İskenderun, Turkiye.
  • Department of Radiation Oncology, Gazi University Faculty of Medicine, Ankara, Turkiye.

ORCID-Profile: Cem Onal, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler

Zitieren

APA

Onal, C., Elmali, A., Demirhan, B., Senturk, E., Erpolat, P., & Guler, O. C. (2026). Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy. The Prostate, 86(8), 961-969. https://doi.org/10.1002/pros.70167

Vancouver

Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC. Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy. The Prostate. 2026;86(8):961-969. doi:10.1002/pros.70167

BibTeX
@article{Onal2026,
  author = {Onal, Cem and Elmali, Aysenur and Demirhan, Birhan and Senturk, Ertugrul and Erpolat, Petek and Guler, Ozan Cem},
  title = {Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {8},
  pages = {961--969},
  doi = {10.1002/pros.70167}
}
Kostenlos starten →